Exclusion Criteria:~* Has had MRI or computerized tomography (CT) of brain within previous 2 years showing
pathology that would be inconsistent with a diagnosis of AD.~* Has known allergy to humanized monoclonal
antibodies.~* Has an ongoing clinically significant laboratory abnormality, as determined by the
investigator.~* Has screening MRI with results showing >4 amyloid related imaging abnormalities H (ARIA-H)
micro-hemorrhages or presence of ARIA-E.~* Has any contraindications for MRI studies, including claustrophobia,
the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.~* Has
received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor or memantine for less than 2
months before randomization. (If a participant has recently stopped AChEIs and/or memantine, he or she must
have discontinued treatment at least 2 months before randomization.)
